Clinical trials: adjuvant therapy
Nasopharyngeal Carcinoma (NPC)
Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma
This study aims to explore the efficacy and safety of risk-adapted adjuvant therapy based on dynamic EBV-DNA changes and MRI in nasopharyngeal carcinoma patients.
- Trial name
- NCT07762976
- Testing
- Observation, Adjuvant therapy
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Fudan University
Breast Cancer, Adjuvant Drug Therapy
The POWER Trial: Personalised Dose Optimisation With Adjuvant Tamoxifen Therapy in Breast cancER
In Sweden, approximately 7000 women are diagnosed with hormone-sensitive breast cancer annually. According to international and national guidelines, most of these women are recommended anti-hormonal therapy for five to ten years…
- Trial name
- POWER (NCT07502820)
- Testing
- Individual dose of tamoxifen, Standard adjuvant therapy of tamoxifen
- Where
- 4 sites in Sweden
- Volunteers
- 1,100 people
- Sponsor
- Karolinska Institutet
Colonic Surgery
Perioperative Zinc Supplementation and Pediatric Colonic Surgical Recovery
The goal of this randomized controlled clinical trial is to evaluate the role of perioperative zinc supplementation on postoperative outcomes (specifically gastrointestinal mucosal integrity and inflammation) in children aged 1…
- Trial name
- NCT07760493
- Testing
- Perioperative Zinc Supplementation
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Alexandria University
Prostate Cancer
CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer
The goal of this clinical trial is to compare systemic therapy combined with cytoreductive prostatectomy with standard of care (SOC) in de novo poly-metastatic hormone sensitive prostate cancer (de novo pmHSPC).
- Trial name
- CREATIVE (NCT06306612)
- Testing
- Systemic Chemohormonal Therapy, Systemic Hormonal Therapy, Cytoreductive Prostatectomy
- Where
- China
- Volunteers
- 192 people
- Sponsor
- RenJi Hospital
Melanoma
Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
This phase II trial seeks to determine the role of nodal radiation therapy after sentinel lymph node biopsy (SLNB) for patients with high risk sentinel lymph node positive melanoma who are planned for immunotherapy without…
- Trial name
- MelPORT (NCT04594187)
- Testing
- Immunotherapy, Quality-of-Life Assessment, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 168 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Axillary Nodal Disease
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or…
- Conditions
- Breast Cancer, Axillary Nodal Disease, Female Breast Cancer, Axilla; Breast
- Trial name
- NCT06092892
- Testing
- Breast Surgery (BCS or mastectomy) with TAD/SNB, Adjuvant Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Alice Chung
Recurrent Head and Neck Squamous Cell Carcinoma
Anti-PD-1 Therapy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to determine whether a perioperative PD-1 antibody-based treatment strategy, consisting of neoadjuvant PD-1 antibody plus chemotherapy followed by adjuvant PD-1 antibody after surgery, improves…
- Trial name
- neo-Recur (NCT07751289)
- Testing
- Neoadjuvant PD-1 antibody plus chemotherapy, surgery, Adjuvant PD-1 antibody
- Volunteers
- 217 people
- Sponsor
- Yanjie Zhang, MD
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
This study investigates the changes in positron emission tomography (PET)/computed tomography (CT) imaging scans during chemoimmunotherapy and radiation therapy treatment in patients with stage IV non-small cell lung cancer.
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT04151940
- Testing
- Positron Emission Tomography, Computed Tomography, Chemotherapy
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Washington
Cancer of Head and Neck, Head and Neck Cancer
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
The goal of this trial is to test the ability of MK-3475 (pembrolizumab) to improve locoregional recurrence and distant metastatic rates in high-risk patients with locally advanced head and neck squamous cell carcinomas (HNSCCs)…
- Conditions
- Cancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck, Carcinoma, Squamous Cell of Head and Neck
- Trial name
- NCT02296684
- Testing
- MK-3475 (neoadjuvant), Surgery, Intensity modulated radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 67 people
- Sponsor
- Washington University School of Medicine
Locally Advanced Rectal Cancer, Older People
Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer
The SHAPERS study is a multicentre, open-label, randomised, pragmatic clinical trial, comparing standard-of-care neoadjuvant treatment options for older (i.e., ≥70 years) subjects with high-risk stage II and stage III rectal…
- Trial name
- SHAPERS (NCT06052332)
- Testing
- Short course radiotherapy, Adjuvant chemotherapy (optional), Total mesorectal excision
- Where
- 19 sites in Belgium
- Volunteers
- 230 people
- Sponsor
- Jules Bordet Institute
Mucopolysaccharidosis IIIA, MPS IIIA
Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA
The main objective of this study is to evaluate the safety/tolerability and efficacy of UX111 (previously known as ABO-102) in participants with Mucopolysaccharidosis IIIA (MPS IIIA).
- Conditions
- Mucopolysaccharidosis IIIA, MPS IIIA, Sanfilippo Syndrome, Sanfilippo A
- Trial name
- NCT04360265
- Testing
- No Investigational Product, Adjuvant Immunomodulatory (IM) Therapy
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 41 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Thymus Neoplasms, Thymic Epithelial Tumor
Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial Tumors
This is a multi-center, open-label, single-arm, prospective interventional study evaluating hypofractionated adjuvant radiotherapy (HART) after radical thymothymectomy in patients with thymic epithelial tumors.
- Conditions
- Thymus Neoplasms, Thymic Epithelial Tumor, Thymoma, Thymic Carcinoma
- Trial name
- THOR (NCT07693855)
- Testing
- Hypofractionated Adjuvant Proton Therapy, Hypofractionated Adjuvant Photon Radiation Therapy
- Where
- 3 sites in Taiwan
- Volunteers
- 69 people
- Sponsor
- National Taiwan University Hospital
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
This clinical trial assesses whether a newly designed algorithm which looks at the genomic signature of each patient's tumor to predict their sensitivity to standard of care treatment verses being placed on a personally designed…
- Conditions
- Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7
- Trial name
- NCT02276443
- Testing
- Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis
- Where
- 5 sites in United States
- Volunteers
- 798 people
- Sponsor
- M.D. Anderson Cancer Center
Pleural Mesothelial Neoplasm
Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma
This phase I trial studies the effect of stereotactic body radiation therapy and immunotherapy in treating patients with mesothelioma.
- Trial name
- NCT04926948
- Testing
- Immunotherapy, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Breast Cancer
Evaluating the Response-Guided Therapy With Neoadjuvant Endocrine Therapy to Optimize Adjuvant Treatment in Premenopausal HR+/HER2- Breast Cancer (JCOG2402, Young HOPE)
Young HOPE/JCOG2402 is a multicenter, randomized phase III study designed to evaluate response-guided therapy following neoadjuvant endocrine therapy to optimize adjuvant treatment in premenopausal HR+/HER2- Breast Cancer.
- Trial name
- YoungHOPE (NCT07671885)
- Testing
- Adjuvant systemic therapy based on pathological findings and ET response, Adjuvant systemic therapy based on pathological findings
- Where
- 49 sites in Japan
- Volunteers
- 950 people
- Sponsor
- Tokyo Women's Medical University
Breast Cancer
Safety of Breast-Conserving Surgery for Multifocal or Multicentric Breast Cancer
The objective of this observational study is to evaluate the oncological safety of breast-conserving surgery combined with standard postoperative radiotherapy in adult female patients diagnosed with multifocal or multicentric…
- Trial name
- NCT07677956
- Testing
- Breast-conserving surgery, postoperative radiotherapy and individualized adjuvant systemic therapy
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Melanoma Stage I, Melanoma Stage III
Adjuvant Therapy of Skin Melanoma With Alpha Interferon and Naderin
The goal of this clinical trial is to learn if adding alpha interferon to standard treatment works to prevent skin melanoma from coming back after surgery.
- Conditions
- Melanoma Stage I, Melanoma Stage III, Melanoma Stage II, Skin Melanoma
- Trial name
- ATSMAIN (NCT07671495)
- Testing
- Surgical resection, Adjuvant Radiotherapy, interferon alfa
- Volunteers
- 278 people
- Sponsor
- MIPO Clinic
Hepatocellular Carcinoma
Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the 7th most common cancer worldwide but is the 4th deadliest, because diagnosis tend to be late and current systemic therapies are poorly efficacious.
- Trial name
- EMPHASIS (NCT05516628)
- Testing
- Surgical Resection, Adjuvant Atezolizumab-Bevacizumab Therapy
- Where
- 6 sites in Singapore
- Volunteers
- 30 people
- Sponsor
- National Cancer Centre, Singapore
Mid-low Locally Advanced Rectal Cancer
rSIFN-co in Combination With Total Neo-adjuvant Therapy in Subjects With Mid-low Locally Advanced Rectal Cancer
This is a multi-center, randomized, phase II study, aimed to evaluate the efficacy of investigational product at a dose of 1800 µg/day when given in combination with TNT.
- Trial name
- rSIFN-co (NCT07662278)
- Testing
- Recombinant Super-Compound Interferon (rSIFN-co), Total Neo-adjuvant therapy
- Volunteers
- 90 people
- Sponsor
- Sichuan Huiyang Life Science and Technology Corporation
Hepatocellular Carcinoma
Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial
Following the results of study IMbrave150, the combination Atezolizumab + Bevacizumab is a promising treatment option for patients with HCC.
- Trial name
- AB-LATE02 (NCT04727307)
- Testing
- Atezolizumab (neoadjuvant), Percutaneous Radiofrequency, Bevacizumab (adjuvant)
- Where
- 19 sites in France
- Volunteers
- 202 people
- Sponsor
- University Hospital, Montpellier